<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Britton D</submitter><funding>Cancer Research UK</funding><funding>Medical Research Council</funding><funding>National Institute for Health Research (NIHR)</funding><pagination>e90948</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3966770</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(3)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>LC-MS/MS phospho-proteomics is an essential technology to help unravel the complex molecular events that lead to and propagate cancer. We have developed a global phospho-proteomic workflow to determine activity of signaling pathways and drug targets in pancreatic cancer tissue for clinical application.&lt;h4>Methods&lt;/h4>Peptides resulting from tryptic digestion of proteins extracted from frozen tissue of pancreatic ductal adenocarcinoma and background pancreas (n = 12), were labelled with tandem mass tags (TMT 8-plex), separated by strong cation exchange chromatography, then were analysed by LC-MS/MS directly or first enriched for phosphopeptides using IMAC and TiO2, prior to analysis. In-house, commercial and freeware bioinformatic platforms were used to identify relevant b</pubmed_abstract><journal>PloS one</journal><pubmed_title>Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets.</pubmed_title><pmcid>PMC3966770</pmcid><funding_grant_id>NIHR-RP-011-053</funding_grant_id><funding_grant_id>16057</funding_grant_id><funding_grant_id>14549</funding_grant_id><funding_grant_id>MR/J006742/1</funding_grant_id><pubmed_authors>Nicholson R</pubmed_authors><pubmed_authors>Sarker D</pubmed_authors><pubmed_authors>Pike I</pubmed_authors><pubmed_authors>Gee J</pubmed_authors><pubmed_authors>Quaglia A</pubmed_authors><pubmed_authors>Ward M</pubmed_authors><pubmed_authors>Selzer S</pubmed_authors><pubmed_authors>Stebbing J</pubmed_authors><pubmed_authors>Zucht HD</pubmed_authors><pubmed_authors>Hoehle C</pubmed_authors><pubmed_authors>Schmid P</pubmed_authors><pubmed_authors>Koncarevic S</pubmed_authors><pubmed_authors>Bohm G</pubmed_authors><pubmed_authors>Prefot P</pubmed_authors><pubmed_authors>Mitra V</pubmed_authors><pubmed_authors>Castellano L</pubmed_authors><pubmed_authors>Heaton N</pubmed_authors><pubmed_authors>Loβner C</pubmed_authors><pubmed_authors>Britton D</pubmed_authors><pubmed_authors>Jung S</pubmed_authors><pubmed_authors>Zen Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets.</name><description>&lt;h4>Objective&lt;/h4>LC-MS/MS phospho-proteomics is an essential technology to help unravel the complex molecular events that lead to and propagate cancer. We have developed a global phospho-proteomic workflow to determine activity of signaling pathways and drug targets in pancreatic cancer tissue for clinical application.&lt;h4>Methods&lt;/h4>Peptides resulting from tryptic digestion of proteins extracted from frozen tissue of pancreatic ductal adenocarcinoma and background pancreas (n = 12), were labelled with tandem mass tags (TMT 8-plex), separated by strong cation exchange chromatography, then were analysed by LC-MS/MS directly or first enriched for phosphopeptides using IMAC and TiO2, prior to analysis. In-house, commercial and freeware bioinformatic platforms were used to identify relevant b</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014</publication><modification>2026-04-29T21:11:54.144Z</modification><creation>2019-03-26T23:24:23Z</creation></dates><accession>S-EPMC3966770</accession><cross_references><pubmed>24670416</pubmed><doi>10.1371/journal.pone.0090948</doi></cross_references></HashMap>